Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment

MT Newswires Live
04-29

Chemomab Therapeutics (CMMB) reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.

Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.

The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.

Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.

Shares of the company rose 1.5% in recent Monday trading.

Price: 1.33, Change: +0.02, Percent Change: +1.53

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10